Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Jentzen

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Academic Radiology|July 31, 2007
Economic image compression of output documentation of the most frequent examinations in nuclear medicineErnst Günter Eising, Walter Jentzen, Rainer Görges, et al.
Clinical Imaging|July 16, 2010
Burn injury by nuclear magnetic resonance imagingErnst G Eising, Justin Hughes, Frank Nolte, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 13, 2019
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancerManuel Weber, Ina Binse, James Nagarajah, et al.
Nuclear Medicine Communications|March 9, 2018
Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activitiesMarcus Ruhlmann, Wilfried Sonnenschein, James Nagarajah, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2010
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancerWalter Jentzen, Robert F Hobbs, Alexander Stahl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Segmentation of PET volumes by iterative image thresholdingWalter Jentzen, Lutz Freudenberg, Ernst G Eising, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2008
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancerWalter Jentzen, Lutz Freudenberg, Ernst G Eising, et al.
Clinical Nuclear Medicine|February 8, 2012
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imagingSandra Julia Rosenbaum-Krumme, Lutz Stefan Freudenberg, Walter Jentzen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2011
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancerLutz S Freudenberg, Walter Jentzen, Alexander Stahl, et al.
Nuclear Medicine Communications|March 5, 2008
Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodulesWalter Jentzen, Rainer Görges, Lutz Freudenberg, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Academic Radiology|July 31, 2007
Economic image compression of output documentation of the most frequent examinations in nuclear medicineErnst Günter Eising, Walter Jentzen, Rainer Görges, et al.
Clinical Imaging|July 16, 2010
Burn injury by nuclear magnetic resonance imagingErnst G Eising, Justin Hughes, Frank Nolte, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 13, 2019
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancerManuel Weber, Ina Binse, James Nagarajah, et al.
Nuclear Medicine Communications|March 9, 2018
Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activitiesMarcus Ruhlmann, Wilfried Sonnenschein, James Nagarajah, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 14, 2010
Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancerWalter Jentzen, Robert F Hobbs, Alexander Stahl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Segmentation of PET volumes by iterative image thresholdingWalter Jentzen, Lutz Freudenberg, Ernst G Eising, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 17, 2008
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancerWalter Jentzen, Lutz Freudenberg, Ernst G Eising, et al.
Clinical Nuclear Medicine|February 8, 2012
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imagingSandra Julia Rosenbaum-Krumme, Lutz Stefan Freudenberg, Walter Jentzen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 13, 2011
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancerLutz S Freudenberg, Walter Jentzen, Alexander Stahl, et al.
Nuclear Medicine Communications|March 5, 2008
Influence of various geometric factors on the iodine-131 uptake measurement for solitary thyroid nodulesWalter Jentzen, Rainer Görges, Lutz Freudenberg, et al.
Pageof 9